I tweaked the lineup in the Health Care portfolio in August. Strategies Why I sold Baxter and CareFusion
When it comes to portfolio moves, we're cold-blooded in our analysis. Strategies A lower stock price never turns a bad company into …
With the population aging, healthcare is a growth sector. Strategies Generic drugmaker Mylan is a smart healthcare play
We analyze our quantitative model every three months, and make adjustments. Strategies Here’s how we rebalanced the Crabtree Technology model
